Evidence map›Paper›PMID 40131977›Full record

ArticlePloS one2025

Epsin bioactive coating reduced in-stent intimal hyperplasia by promoting early phase reendothelialization and inhibiting smooth muscle cell proliferation.

Wenxu Zhang, Hao Lin, Zechao Zhu, Kunyuan Zhu, Shijun Bi, Xinyu Yang, Guangzhi Hao, Dandan Gao, Da Huo, Shanshan Chen and 4 more

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Targeting Arterial Dysfunction in Cardiovascular Disease Using Stem Cell-Based Therapies.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Wenxu ZhangDepartment of Neurosurgery, General hospital of Northern Theater Command, Shenyang, China.ORCID https://orcid.org/0009-0008-8289-0524
Hao LinInstitute of Metal Research, Chinese Academy of Sciences, Shenyang, China.
Zechao ZhuDepartment of Neurosurgery, General hospital of Northern Theater Command, Shenyang, China.
Kunyuan ZhuDepartment of Neurosurgery, General hospital of Northern Theater Command, Shenyang, China.
Shijun BiDepartment of Neurosurgery, General hospital of Northern Theater Command, Shenyang, China.
Xinyu YangDepartment of Neurosurgery, General hospital of Northern Theater Command, Shenyang, China.
Guangzhi HaoDepartment of Neurosurgery, General hospital of Northern Theater Command, Shenyang, China.
Dandan GaoDepartment of Neurosurgery, General hospital of Northern Theater Command, Shenyang, China.
Da HuoDepartment of Neurosurgery, General hospital of Northern Theater Command, Shenyang, China.
Shanshan ChenInstitute of Metal Research, Chinese Academy of Sciences, Shenyang, China.
Jing ZhaoInstitute of Metal Research, Chinese Academy of Sciences, Shenyang, China.
Meixia LiuInstitute of Metal Research, Chinese Academy of Sciences, Shenyang, China.
Pengyu PanDepartment of Neurosurgery, General hospital of Northern Theater Command, Shenyang, China.
Guobiao LiangDepartment of Neurosurgery, General hospital of Northern Theater Command, Shenyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, interventional surgery has become a treatment for ischemic stroke due to its low risk of injury. However, the occurrence of restenosis hinders the long-term effectiveness and safety of stent implantation. At present, drug-eluting stents mainly prevent the stenosis of drug-eluting stents by inhibiting the proliferation of smooth muscle cells (SMCs). However, these drugs cause damage to endothelial cells (ECs), prevent timely re endothelialization of blood vessels, and increase the risk of late thrombosis and late restenosis. EPS-15-interacting protein 1 (Epsin1)- EPS-15-interacting protein 2 (Epsin2)-shrna coated stents have the potential to promote early endothelialization and inhibit restenosis, which contributes to the candidate development of novel drug coated stents. We found that the expression of Epsin was elevated in the mouse carotid artery ligation model, and the intimal hyperplasia(IH) could be reduced by intervening Epsin. Epsin in cultured endothelial cells was interfered to study proliferation and migration functions, and its role in cocultured endothelial cells and smooth muscle cells was evaluated. In addition, we explored the potential therapeutic benefits of inhibiting Epsin in a porcine model using scaffolds coated with plasmids containing Epsin short hairpin RNA (shRNA). Our study showed that the expression of Epsin1 and Epsin2 was elevated in the proliferative intima of mice, and the inhibition of Epsin reduced the proliferation of neointima in mice. The inhibition of Epsin led to enhanced proliferation and migration of endothelial cells, and maintained a healthy cell membrane potential. In cocultured cells, inhibition of Epsin resulted in reduced proliferation and migration of smooth muscle cells. In a porcine carotid artery model, Epsin shRNA coated scaffolds promoted early re endothelialization and reduced IH. These results suggest that Epsin plays a crucial role in endothelial and smooth muscle cell proliferation and migration functions, and its inhibition may be a potentially effective therapeutic strategy to prevent in stent stenosis.

Indexed as

Adaptor Proteins, Vesicular TransportDrug-Eluting StentsMyocytes, Smooth MuscleRe-EpithelializationTunica IntimaAnimalsCarotid ArteriesCell MovementCell ProliferationEndothelial CellsHumansHyperplasiaMaleMiceMice, Inbred C57BLSwineAdaptor Proteins, Vesicular Transportepsin

Identifiers

PMID40131977
PMCPMC11936285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.